Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

Anti-Human CD276 Antibody (SAA0090)

Catalog #:   FHJ04010 Specific References (50) DATASHEET
Host species: Human
Isotype: IgG1, kappa
Applications: FCM
Accession: Q5ZPR3
Overview

Catalog No.

FHJ04010

Species reactivity

Human

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Conjugation

Unconjugated

Target

CD276, B7-H3, Costimulatory molecule, B7H3, 4Ig-B7-H3, B7 homolog 3, CD276 antigen

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q5ZPR3

Applications

FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA0090

Data Image
References

Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastoma., PMID:40518621

PARP inhibitors accumulate B7-H3 on fibroblasts via blocking autophagic flux to potentiate immune evasion in ovarian cancer., PMID:40497528

m276-SL-PBD eradicates tumors and instigates long-lasting tumor-free survival in Merkel cell carcinoma preclinical models., PMID:40384933

Actionable heterogeneity of hepatocellular carcinoma therapy-induced senescence., PMID:40374812

Biomarkers of response to antibody-drug conjugates (TROP2 and nectin-4) and the immune microenvironment (NKG7, PD-L1, and B7-H3) in penile squamous cell carcinoma., PMID:40327767

Targeting site-specific N-glycosylated B7H3 induces potent antitumor immunity., PMID:40229277

Codelivery of apigenin, FdUMP and CD276 antibody synergistic inhibit colorectal cancer by ferroptosis-apoptosis-pyroptosis and CD276 blockade., PMID:40224726

B7H3 in Gastrointestinal Tumors: Role in Immune Modulation and Cancer Progression: A Review of the Literature., PMID:40214484

Molecular Imaging of B7-H3-Targeting Bispecific T Cell-Engaging Antibody MGD009 in Glioblastoma Models., PMID:40183579

Advances in adoptive cell therapies in small cell lung cancer., PMID:40160238

The AURKA inhibitor alters the immune microenvironment and enhances targeting B7-H3 immunotherapy in glioblastoma., PMID:39928563

B7-H3-liquid biopsy for the characterization and monitoring of the dynamic biology of prostate cancer., PMID:39914189

Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study., PMID:39863300

Identification and characterization of CD83 and CD276 as markers of dendritic cells in olive flounder (Paralichthys olivaceus)., PMID:39848419

A humanized anti-b7h3×4-1BB bispecific antibody exerts potent antitumour effects through the activation of innate and adaptive immunity., PMID:39847994

Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targets., PMID:39825754

An immunohistochemical and molecular genetic study of 60 colorectal carcinoma brain metastases in pursuit of predictive biomarkers for cancer therapy., PMID:39824298

Unraveling the dynamics of B7-H3-targeting therapeutic antibodies in cancer through PET imaging and antibody pharmacokinetics., PMID:39814321

Engineered T cells secreting αB7-H3-αCD3 bispecific engagers for enhanced anti-tumor activity against B7-H3 positive multiple myeloma: a novel therapeutic approach., PMID:39806405

PRMT5-Mediated ALKBH5 Methylation Promotes Colorectal Cancer Immune Evasion via Increasing CD276 Expression., PMID:39781264

The inhibitory effects of nimotuzumab on CD276 expression and immune escape in head and neck squamous cell carcinoma: Insights into anticancer mechanisms., PMID:39778280

Statins inhibit onco-dimerization of the 4Ig isoform of B7-H3., PMID:39763965

Assessment of targets of antibody drug conjugates in SCLC., PMID:39748112

B7-H3 in glioblastoma and beyond: significance and therapeutic strategies., PMID:39664380

Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response., PMID:39615894

Prognostic value of B7-H3 expression in metastatic renal cell carcinoma and its impact on immunotherapy response., PMID:39614178

Preclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicity., PMID:39562005

Ultrasound Molecular Imaging Enhances High-Intensity Focused Ultrasound Ablation on Liver Cancer With B7-H3-Targeted Microbubbles., PMID:39431644

Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein binders., PMID:39420062

Targeting CD276 for T cell-based immunotherapy of breast cancer., PMID:39367484

Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses., PMID:39357981

Development of a Specifically Labeled 89Zr Antibody for the Noninvasive Imaging of Tumors Overexpressing B7-H3., PMID:39322604

A B7-H3-Targeted CD28 Bispecific Antibody Enhances the Activity of Anti-PD-1 and CD3 T-cell Engager Immunotherapies., PMID:39301613

B7-H3 promotes nasopharyngeal carcinoma progression by regulating CD8+ T cell exhaustion., PMID:39267471

Multiplexed Spatial Imaging at the Single-Cell Level Reveals Mutually Exclusive Expression of B7 Family Proteins., PMID:39244158

Genetically engineered CD276-anchoring biomimetic nanovesicles target senescent escaped tumor cells to overcome chemoresistant and immunosuppressive breast cancer., PMID:39226654

B7 homolog 3 in pancreatic cancer., PMID:39193002

A Dual-Payload Antibody-Drug Conjugate Targeting CD276/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer., PMID:39186778

ITGB6 modulates resistance to anti-CD276 therapy in head and neck cancer by promoting PF4+ macrophage infiltration., PMID:39152118

Diet restriction enhances the effect of immune checkpoint block by inhibiting the intratumoral mTORC1/B7-H3 axis., PMID:39132973

CAR T-cells targeting FGFR4 and CD276 simultaneously show potent antitumor effect against childhood rhabdomyosarcoma., PMID:39043633

Expression and Prognostic Value of a Novel B7-H3 (CD276) Antibody in Acute Myeloid Leukemia., PMID:39001517

Differential Immune Checkpoint Protein Expression in HNSCC: The Role of HGF/MET Signaling., PMID:39000441

Development of DNA aptamers targeting B7H3 by hybrid-SELEX: an alternative to antibodies for immuno-assays., PMID:38866941

Targeting both GD2 and B7-H3 using bispecific antibody improves tumor selectivity for GD2-positive tumors., PMID:38853889

Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting., PMID:38767611

The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas., PMID:38765008

CD276 regulates the immune escape of esophageal squamous cell carcinoma through CXCL1-CXCR2 induced NETs., PMID:38724465

B7-H3-Targeting Chimeric Antigen Receptors Epstein-Barr Virus-specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3-positive Solid Tumors., PMID:38717140

Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody., PMID:38637557

Datasheet
$ 225
Product specifications
50 μg 225 100 μg 372

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human CD276 Antibody (SAA0090) [FHJ04010]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only